Evaxion A/S (EVAX)
NASDAQ: EVAX · Real-Time Price · USD
2.930
-0.150 (-4.87%)
Oct 30, 2026, 4:00 PM EDT - Market closed
Evaxion Revenue
Evaxion had revenue of $7.49M in the twelve months ending June 30, 2026, up 135.86% year-over-year. In the year 2025, Evaxion had annual revenue of $7.53M with 125.12% growth. That makes Evaxion the 38,561st largest company in the world by revenue and 5,078th in the United States.
Revenue (ttm)
$7.49M
Revenue Growth
+135.86%
P/S Ratio
3.26
Revenue / Employee
$162,848
Employees
46
Market Cap
24.44M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.53M | 4.18M | 125.12% |
| Dec 31, 2024 | 3.34M | 3.27M | 4,480.82% |
| Dec 31, 2023 | 73.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Celularity | 18.67M |
| Immutep | 13.79M |
| BeyondSpring | 1.88M |
| ABVC BioPharma | 797.92K |
| CervoMed | 331.30K |
EVAX News
- 2 days ago - Evaxion receives International Prix Galien Award for AI-Immunology™ as best digital health solution - GlobeNewsWire
- 2 days ago - Evaxion Transcript: Study update - Transcripts
- 2 days ago - Evaxion Slides: Study update - Filings
- 9 days ago - Evaxion Biotech presents three-year immune and clinical outcome data for EVX-01 - TheFly
- 9 days ago - Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01 - GlobeNewsWire
- 10 days ago - Evaxion Slides: Corporate presentation - Filings
- 13 days ago - Evaxion Biotech reports three-year clinical outcome data for EVX-01 - TheFly
- 13 days ago - Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01 - GlobeNewsWire